On The Pen GLP-1 News

On The Pen GLP-1 News

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.


Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(197)

He Took Retatrutide 40mg and Proved a Point

He Took Retatrutide 40mg and Proved a Point

This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safe...

5 Mai 36min

Eli Lilly Earnings Call Recap: Q1 2026

Eli Lilly Earnings Call Recap: Q1 2026

We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of...

30 Apr 25min

SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story

SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story

https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real ...

28 Apr 18min

BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!

BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!

Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enfo...

23 Apr 40min

Retatrutide Could Change Everything… But Who Actually Gets It?

Retatrutide Could Change Everything… But Who Actually Gets It?

ON THE PEN RESOURCES AND LINKS: HTTPS://WWW.OTPLINKS.COMWhat if the most powerful obesity drug ever created ends up being the one you can’t get?That’s the real conversation around retatrutide right no...

21 Apr 29min

Ozempic Personality With Dr Spencer Nadolsky

Ozempic Personality With Dr Spencer Nadolsky

This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid intervi...

19 Apr 42min

Foundayo GLP-1 Pill: FDA Needs More Data

Foundayo GLP-1 Pill: FDA Needs More Data

Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require...

14 Apr 20min

GLP-1 Access Is EXPLODING… But Something Else Is Happening

GLP-1 Access Is EXPLODING… But Something Else Is Happening

If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave br...

7 Apr 23min

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
hvordan-har-du-det-mann
leger-om-livet
psykodrama
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-skravla-gar
foreldreradet
rss-garne-damer
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
morten-ramm-lar-kakla-ga-til-du-sovner
g-punktet
rss-kunsten-a-leve
klimaks
hjernesterk
aftenbladet-intervjuer
treningsprat
kjed-deg-i-sovn-verdens-kjedeligste-podcast
helsetipspodden